Stay up to date with the latest news, press releases and events related to Nyctea Technologies and its products
January 2024
The collaboration leverages Nyctea's unique expertise and its proprietary Nyctea® platformtechnology to improve the purification process for a drug compound that AstraZeneca is developing within its Research and Development program.
Nyctea Technologies is on the list of best start-ups in Sweden
November 2023
Nyctea Technologies were selected on 33-listan, an annual list of best start-ups published by NyTeknik Sweden's leading newspaper on technology.
June 2023
Breaking free and soaring to new heights! We're thrilled to announce that we are bidding farewell to our current lab hosted by @Chalmers and spreading our wings in our very own state-of-the-art facility within AstraZeneca's BioVentureHub. 🌟
Harnessing the power of collaboration and scientific excellence, we are dedicated to shaping a brighter future for patients worldwide. And what better place to do it than right here!
Astra Zeneca's BioventureHub serves as a catalyst for collaboration, fostering synergy among groundbreaking companies and researchers.
May 2023
Nyctea Technologies has been recognized on IVA's prestigious 100 List of Swedish Innovations! 💡
Being featured on IVA's 100 List is a testament to Nyctea's innovative spirit and dedication to scientific excellence. It showcases the tremendous potential of our cutting-edge technologies and their ability to shape the future of healthcare in Sweden and beyond.
IVA's 100 List celebrates the very best and brightest innovations from Sweden, spanning groundbreaking technologies to visionary solutions. This curated collection highlights the exceptional potential of innovators in various industries, driving positive transformations and paving the way for a brighter future.
May 2023
Better together! Nyctea Technologies has joined hands with AdBIOPRO, the renowned competence centre for advanced bioproduction. 🤝
By combining the innovative capabilities of Nyctea Technologies with the expertise and resources of AdBIOPRO, this collaboration aims to revolutionize bioproduction methods, enhance sustainability, and propel the biotech industry forward.
AdBIOPRO is the Competence Centre for Advanced BioProduction, started in 2017. The centre has now been granted continuation for a new period of 5 years with a total budget of 112 mkr. This highly multi-disciplinary Centre gathers eight academic groups as well as 16 industrial partners.
March 2023
So what happened at TESTA Challenge 2023? What technical progress did our participation led to in bioprocessing of gene therapybiomolecules? Watch the video!
January 2023
Nyctea has been selected as one of the participants in TESTA Challenge 2023! 🚀
Nyctea participated already in 2022 and brought back valuable insights and results on how to improve the product development and production cycle for upcoming customer deliveries. This year will not be an exception!
Testa Center is a non-profit company owned by Cytiva. Testa Center is a major initiative between the Swedish government and Cytiva to secure the growth of the life science industry and its manufacturing capabilities. The main objective of Testa Center is to bridge the gap from discovery to industrialization.
Don't miss out on the opportunity to connect with Nyctea Technologies on LinkedIn. Join our journey and be part of the exciting advancements and transformative impact we are making in the field of biotech!
A world with
affordable medicine
